The Journal of Immunology, Vol 158, Issue 2 807-815, Copyright © 1997 by American Association of Immunologists

ARTICLES

Antagonism of vaccine-induced HIV-1-specific CD4+ T cells by primary HIV-1 infection: potential mechanism of vaccine failure

SJ Kent, PD Greenberg, MC Hoffman, RE Akridge and MJ McElrath
Department of Medicine, University of Washington School of Medicine, Seattle 98145, USA.

Prior immunity to HIV-1 elicited by vaccination may modify subsequent responses upon exposure to infectious HIV-1. An HIV-1-uninfected person entered in a vaccine trial that included immunizations to HIV-1(LAI) envelope with a recombinant vaccinia vector and recombinant protein developed envelope-specific CD4+ T cell responses, including proliferative and cytolytic responses, but was not protected from a high risk HIV-1 exposure. CD4+ T cell clones derived from blood at the peak of vaccine-induced immunity recognized and lysed autologous target cells expressing four distinct regions within the HIV-1(LAI) envelope region; three of these CTL clones also recognized targets expressing envelope from a similar viral subtype, HIV-1(MN). The epitope specificity of CD4+ clone 9G8, recognizing both HIV-1(LAI) and HIV- 1(MN) envelope, was within the 571-590 amino acid envelope region. Sequence analysis of the first infectious autologous strain revealed two amino acid mutations within this region. The 9G8 CTL clone induced by immunization failed to recognize targets expressing the corresponding CTL epitope from the infecting virus. Moreover, a peptide based on the epitope sequence of the infecting isolate antagonized the vaccine-induced CTL clone such that the CTL clone was no longer able to recognize the vaccine strain or HIV-1(MN) epitope. These findings suggest a potentially novel mechanism associated with vaccine failure whereby the infecting virus may not only escape from CTL activity, but also alter the ability of CTL to recognize other variants in an individual.

This article has been cited by other articles:

				S. Chea, C. J. Dale, R. De Rose, I. A. Ramshaw, and S. J. Kent Enhanced Cellular Immunity in Macaques following a Novel Peptide Immunotherapy J. Virol., March 15, 2005; 79(6): 3748 - 3757. [Abstract] [Full Text] [PDF]

				U. Malhotra, S. Holte, T. Zhu, E. Delpit, C. Huntsberry, A. Sette, R. Shankarappa, J. Maenza, L. Corey, and M. J. McElrath Early Induction and Maintenance of Env-Specific T-Helper Cells following Human Immunodeficiency Virus Type 1 Infection J. Virol., February 15, 2003; 77(4): 2663 - 2674. [Abstract] [Full Text] [PDF]

				S. Barcy and L. Corey Herpes Simplex Inhibits the Capacity of Lymphoblastoid B Cell Lines to Stimulate CD4+ T Cells J. Immunol., May 15, 2001; 166(10): 6242 - 6249. [Abstract] [Full Text] [PDF]

				L. Frasca, P. Del Porto, L. Tuosto, B. Marinari, C. Scotta, M. Carbonari, A. Nicosia, and E. Piccolella Hypervariable Region 1 Variants Act as TCR Antagonists for Hepatitis C Virus-Specific CD4+ T Cells J. Immunol., July 15, 1999; 163(2): 650 - 658. [Abstract] [Full Text] [PDF]

				S. J. Kent, A. Zhao, S. J. Best, J. D. Chandler, D. B. Boyle, and I. A. Ramshaw Enhanced T-Cell Immunogenicity and Protective Efficacy of a Human Immunodeficiency Virus Type 1 Vaccine Regimen Consisting of Consecutive Priming with DNA and Boosting with Recombinant Fowlpox Virus J. Virol., December 1, 1998; 72(12): 10180 - 10188. [Abstract] [Full Text] [PDF]

				C. Lekutis and N. L. Letvin Substitutions in a Major Histocompatibility Complex Class II-Restricted Human Immunodeficiency Virus Type 1 gp120 Epitope Can Affect CD4+ T-Helper-Cell Function J. Virol., July 1, 1998; 72(7): 5840 - 5844. [Abstract] [Full Text] [PDF]

				L. Mortara, F. Letourneur, H. Gras-masse, A. Venet, J.-G. Guillet, and I. Bourgault-Villada Selection of Virus Variants and Emergence of Virus Escape Mutants after Immunization with an Epitope Vaccine J. Virol., February 1, 1998; 72(2): 1403 - 1410. [Abstract] [Full Text] [PDF]